Comparative Pharmacology
Head-to-head clinical analysis: BETAGAN versus BETAXOLOL HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETAGAN versus BETAXOLOL HYDROCHLORIDE.
BETAGAN vs BETAXOLOL HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Beta-1 selective beta-adrenergic receptor antagonist; reduces intraocular pressure by decreasing aqueous humor production.
Selective beta-1 adrenergic receptor antagonist; reduces heart rate, myocardial contractility, and blood pressure.
Instill 1 drop of 0.25% or 0.5% solution into the affected eye(s) twice daily.
10-20 mg orally once daily; maximum 20 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 10-15 hours in adults; prolonged in renal impairment (up to 30 hours).
Terminal elimination half-life: 14–22 hours (mean 16 hours); sufficient for once-daily dosing in hypertension; prolonged in renal impairment.
Primarily renal excretion of unchanged drug and metabolites; about 80% eliminated in urine, 20% in feces as unchanged drug or glucuronide conjugates.
Renal: 80% (as unchanged drug and inactive metabolites), Fecal: 20%
Category C
Category C
Beta-Blocker
Beta-Blocker